Diagnose Tuberculosis with IP-10
Ready to embrace the future of T-cell based Tuberculosis diagnosis? Three tubes, two choices: Rapid Test or ELISA. Complete the form below, and our team will reach out with more information about [...]
Obligation to report of chlamydia trachomatis serotypes L1- L3
Please note: The proof of chlamydia trachomatis serotypes L1- L3 is to be reported since September 2022 We would like to draw your attention to the crucial importance of differentiating between [...]
Increasing number of syphilis infections
Dramatic rise in syphilis infections: Warning of underestimated risk In recent years, the healthcare world has seen a concerning surge in syphilis infections. Between 2020 and 2022, reported [...]
Top priority at R-Biopharm: the IVDR
The EU has created a new legal framework for the quality and safety of in-vitro medical devices, namely the IVDR (Regulation on in-vitro diagnostic medical devices), which sets legally binding [...]
R-Biopharm announces quality products distribution agreement with Microbix
Mississauga, Canada and Darmstadt, Germany, 15th May 2020 – R-Biopharm AG and Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator, announces the appointment of R-Biopharm [...]